The novel circ_0084904/miR-802/MAL2 axis promotes the development of cervical cancer

2022 ◽  
Vol 22 (1) ◽  
pp. 100600
Author(s):  
Lu Chen ◽  
Hongying Li ◽  
Dongmei Yao ◽  
Qian Zou ◽  
Weichang Yu ◽  
...  
Keyword(s):  
2004 ◽  
Vol 190 (1) ◽  
pp. 60-66 ◽  
Author(s):  
Stefania Cane' ◽  
Eliana Bignotti ◽  
Stefania Bellone ◽  
Michela Palmieri ◽  
Luis De Las Casas ◽  
...  

2012 ◽  
Vol 22 (6) ◽  
pp. 930-936 ◽  
Author(s):  
Zhengrong Sun ◽  
Jianhua Liu ◽  
Guili Wang ◽  
Weiqiang Zhou ◽  
Chao Liu ◽  
...  

IntroductionIn cervical cancer, human papillomavirus (HPV) 18 is predominantly related to adenocarcinomas. Variant lineages of HPV type 16 have been well characterized, whereas the knowledge about HPV 18 variants is limited in Northeast China.MethodsTo identify prevalent and novel HPV 18 variants in Northeast China, theE6,E7, andL1genes of HPV 18 from patients with cervical lesion were amplified and sequenced, and intratypic variants were analyzed by comparing to the known phylogenetic branches.ResultsThe HPV-18 E6 variants of our studied strains belong to 2 main branches: Asian-American (AA) variants in 81.5% and European (E) variants in 18.5%. Strains with variations of C287G, T482C, and C519A inE6and C751T inE7were novel variants. All theL1genes of the analyzed HPV 18 strains had 4 C-G transversions at nucleotide positions of 5701, 6460, 6625, and 6842 and one G-A transition at position 5503. Moreover, strains with L1 nucleotide variations of A5920T, A6431T, and G6987A leading to amino acid substitutions of A164V, Q334P/H, and D520N are novel variants.ConclusionsBased on theE6gene, the prevalent HPV 18 in Northeast China was AA and E variants. Besides some common variations reported before, some new variations in theE6,E7, andL1genes were found. Data about the novel variations found in theL1gene of HPV 18 variants may be helpful to design the diagnostic reagents and vaccine for naturally infected HPV 18 in Northeast China.


Brachytherapy ◽  
2018 ◽  
Vol 17 (5) ◽  
pp. 775-781 ◽  
Author(s):  
Franziska Walter ◽  
Cornelius Maihöfer ◽  
Lars Schüttrumpf ◽  
Justus Well ◽  
Alexander Burges ◽  
...  

2013 ◽  
Vol 107 (1) ◽  
pp. 88-92 ◽  
Author(s):  
Steven Petit ◽  
Piotr Wielopolski ◽  
Reneé Rijnsdorp ◽  
Jan-Willem Mens ◽  
Inger-Karine Kolkman-Deurloo
Keyword(s):  

Human Cell ◽  
2021 ◽  
Vol 34 (3) ◽  
pp. 878-888
Author(s):  
Tian Jun ◽  
Wang Chen ◽  
Cheng Hailing ◽  
Wang Ning ◽  
Cao Qinxue

2021 ◽  
Vol 22 (7) ◽  
pp. 3774
Author(s):  
Abidur Rahman ◽  
Makoto Kobayashi ◽  
Kotaro Sugimoto ◽  
Yuta Endo ◽  
Manabu Kojima ◽  
...  

Background: Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications. Methods: We generated a monoclonal Ab (mAb) against human/mouse CLDN12 and verified its specificity. By performing immunohistochemical staining and semiquantification, we evaluated the relationship between CLDN12 expression and clinicopathological parameters in tissues from 138 cases of cervical cancer. Results: Western blot and immunohistochemical analyses revealed that the established mAb selectively recognized the CLDN12 protein. Twenty six of the 138 cases (18.8%) showed low CLDN12 expression, and the disease-specific survival (DSS) and recurrence-free survival rates were significantly decreased compared with those in the high CLDN12 expression group. We also demonstrated, via univariable and multivariable analyses, that the low CLDN12 expression represents a significant prognostic factor for the DSS of cervical cancer patients (HR 3.412, p = 0.002 and HR 2.615, p = 0.029, respectively). Conclusions: It can be concluded that a reduced CLDN12 expression predicts a poor outcome for cervical cancer. The novel anti-CLDN12 mAb could be a valuable tool to evaluate the biological relevance of the CLDN12 expression in diverse cancer types and other diseases.


2020 ◽  
Vol 21 (4) ◽  
pp. 305-311
Author(s):  
O.A. Pardabekova

The incidence and mortality from cervical cancer (CC) remains high. There are few effective options among chemotherapeutic agents for the treatment of recurrent and metastatic CC. One of the novel therapeutic approaches is to induce anti-cancer immunity by immune checkpoint inhibitors (ICI). The search for prognostic biomarkers to improve the efficacy of immunotherapy is ongoing. The efficacy and safety of ICI, either used as monotherapy or in combination with chemotherapy, radiation therapy, is being evaluated in several clinical studies. Early results are promising, making ICI an important field of research in the development of novel therapies for CC.


2008 ◽  
Vol 18 (3) ◽  
pp. 534-539
Author(s):  
C. X CAO ◽  
J. MA ◽  
M. XUN ◽  
X. XUE ◽  
P. CHEN ◽  
...  

The novel human oncogenehWAPLis associated with uterine cervical cancer. The HPV16 E5 oncoprotein could induce genomic instability in normal human cells. However, the mechanism of E5 interaction with hWAPL still awaits definition. In our present studies, the eukaryotic expression plasmids, pcDNA3-hWAPL and pcDNA3-hWAPL-E5 were constructed and carried out to vaccinate mice directly. The result that indicated the polyclonal antibody titer in immunized mice sera was increased by enzyme-linked immunosorbent assay. In addition, the proliferative responses of immunized mice spleen cells showed the optical densities values in vaccinated group remarkably higher than that in the control group. In conclusion, the recombinant plasmids could induce strong humoral and cellular immune response and exhibited great potential as therapeutic targets in the treatment of cervical cancer. However, the result didn't show significant difference in group with coexpression of HPV16 E5–hWAPL and group with only hWAPL expression. Consistent with these observations, we demonstrated that HPV16 E5 was not the optimal factor to cooperate with hWAPL in gene therapy.


Sign in / Sign up

Export Citation Format

Share Document